Adaptive Radiotherapy Tested Before Surgery for Rectal Cancer
Tests adjusted radiation treatment before surgery in adults with rectal cancer.
Plain-language title generated from the registry record
Registry title: Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer
Key facts
- Where
- Bergen, NorwaySee the site
Where in Norway
- Haukeland University HospitalBergen, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Haukeland University Hospital
- Trial code
- NCT05883800
- Record updated
- 19 March 2024
- Original description
Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment).Read full original descriptionShow less
TNT-RECORD:Total Neoadjuvant Treatment in Rectal Cancer With On-couch Adaptive Radiotherapy
Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment).
This study therefore investigates the benefit of on-couch adaptation for locally advanced rectal cancer patients undergoing this treatment regime.
Inclusion: Patients with loco-regional advanced rectal adenocarcinoma with clinical indications for short-course with TNT chemotherapy i.e. having at least one of the following T4a, CRM+ (≤1 mm), N1c, N2 or extramural vascular invasion (EMVI+). Patients presenting at least one of these criteria in addition to involvement of the pelvic sidewall lymph nodes (PSW) can optionally be considered; ECOG status ≤ 1; Being willing and able to give full written consent for participation.
Exclusion: Previous rectal cancer treatment; Previous irradiation to the treatment area e.g. prostate cancer; Hip prosthesis; Contraindications to MRI; Pregnancy; Abnormal DPYD genotype; Known contraindication to 5-FU, Capecitabine or Oxaliplatin as judged by the investigators.